THAP9 encodes a domesticated P-element DNA transposase that retains catalytic activity despite its integration into the human genome 1. The protein specifically recognizes a bipartite consensus motif (5'-TXXGGGX(A/T)-3') and catalyzes DNA transposition through an RNase-H-like domain containing conserved acidic residues 2. THAP9 undergoes homo-oligomerization via its amino-terminal DNA-binding domain in a DNA-dependent manner, a process critical for transposition activity 3. Clinically, THAP9 and its antisense partner THAP9-AS1 function as a bidirectional gene pair with coordinated expression and significant prognostic value across multiple cancer types 4. Elevated THAP9-AS1 expression associates with poor overall and disease-free survival in esophageal squamous cell carcinoma, hepatocellular carcinoma, and pancreatic ductal adenocarcinoma 567. In ESCC, THAP9-AS1 acts as a competing endogenous RNA for miR-133b to upregulate SOX4 in a positive feedback loop 5, while in PDAC it enhances YAP signaling through both ceRNA activity and direct protein binding 7. These regulatory circuits promote cell proliferation and metastatic phenotypes, positioning the THAP9/THAP9-AS1 axis as a potential therapeutic target and independent prognostic biomarker across cancers.